Millendo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.millendo.com
Clinical Trials
5
Active:3
Completed:2
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
Phase 2
Completed
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Drug: ATR-101
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Millendo Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02804178
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Phase 1
Completed
- Conditions
- Adrenal CancerACCAdrenocortical Carcinoma
- Interventions
- Drug: ATR-101
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Millendo Therapeutics, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01898715
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸National Institutes of Health/National Cancer Institute, Bethesda, Maryland, United States
🇺🇸University of Michigan Cancer Center, Ann Arbor, Michigan, United States
News
No news found